Integration of Surgery and Systemic Therapy In the Management of Renal Cell Carcinoma By Christopher Wood, MD, FACS
This is a monthly Grand Rounds to help educate our Urology Faculty, Residents, Allied Healthcare Providers, and Community Physicians. It is designed around Urologic topics to assist in updated medical topics and care.
Target Audience
- Urology Faculty
- Residents
- Allied Healthcare Providers
- Community Physicians
Learning Objectives
- The participant will be able to understand the role of cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
- The participant will be able to understand the role and safety of pre-surgical therapy in the management of advanced RCC
- The participant will be able to understand the proper integration of surgery and systemic therapy in the management of locally advanced RCC
Activity Director
Ken Jacobsohn, MD
Assistant Professor
Department of Urology
Board Certified - American Board of Urology
No relevent financial relationships to disclose
Planning Committee
William See, MD
Chairman, Professor
Department of Urology
Board Certified - American Board of Urology
No relevant financial relationships to disclose
Christopher Wood, MD, FACS
Douglas E. Johnson, M.D. Professorship
Professor & Deputy Chairman
Department of Urology
UT MD Anderson Cancer Center
Houston, Texas
Dr. Wood has disclosed a financial relationship with Pfizer, Inc. as a consultant & Advisory Board
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.